Has Frank Rosenbaum received payments from drug or device companies?

Yes. Drug and device makers reported $2,057 in general payments to Frank Rosenbaum across 87 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Frank Rosenbaum did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Frank Rosenbaum come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Frank Rosenbaum

Ophthalmology · Lansing, MINPI 1598783623

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 87 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Kala Pharmaceuticals, Inc. at 29.0% of the total. Reporting peaked in 2019 at $1,299 and has fallen 97.1% since, to $37 in 2022.

$2,057in general payments, 2019–2025

Across 87 payments — averaging $23.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Kala Pharmaceuticals, Inc.$596
Mallinckrodt Enterprises LLC$283
Novartis$254
Bausch & Lomb, A Division Of Bausch Health US, LLC$223
Ivantis, Inc$162
Mallinckrodt Hospital Products Inc.$92
plus $447 from 13 others

What the payments were for

Food & beverage$2,057100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Kala Pharmaceuticals, Inc.	23	$596
Mallinckrodt Enterprises LLC	14	$283
Novartis	10	$254
Bausch & Lomb, A Division Of Bausch Health US, LLC	10	$223
Ivantis, Inc	1	$162
Mallinckrodt Hospital Products Inc.	5	$92
Johnson & Johnson Surgical Vision, Inc.	2	$91
Alcon	3	$57
Shire North American Group Inc	4	$54
AbbVie	3	$45
Aerie Pharmaceuticals, Inc.	2	$37
Coopervision Inc.	1	$34
Carl Zeiss Meditec, Inc.	1	$32
Sun Pharmaceutical Industries Inc.	2	$25
NEW World Medical,inc.	1	$16
Biotissue Holdings Inc.	2	$15
Ocular Therapeutix, Inc.	1	$14
Dompe US, Inc.	1	$14
Eyepoint US, Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

INVELTYS$222
Hydrus$162
XIIDRA$121

How this compares

$2,057 in reported general payments places this provider in the 60th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan →

Other ophthalmology in Lansing

Manjool ShahAnn Arbor$609K
Gregory KatzYpsilanti$401K
Timothy PageBirmingham$250K
David ZacksAnn Arbor$177K
Scott WesthouseGrand Rapids$138K
Bret HughesDetroit$123K
Pradeepa YoganathanDetroit$115K
Jason MillerAnn Arbor$104K
David TukelDearborn$91K
Yannis PaulusAnn Arbor$85K

See the full list for Michigan →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →